Greehey CCRI Archives
Frontiers in Oncology: Nanoformulation of Talazoparib Increases Maximum Tolerated Doses in Combination With Temozolomide for Treatment of Ewing Sarcoma
December 17, 2019The Pediatric Preclinical Testing Program previously identified the PARP inhibitor talazoparib (TLZ) as a means to potentiate temozolomide (TMZ) activity for the treatment of Ewing sarcoma. However, the combination of TLZ and TMZ has been toxic in both …
SCITECH EUROPA: Preclinical Drug Development for Childhood Cancers
December 2, 2019Cell Reports: Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design
November 5, 2019Author links open overlay panelJo LynneRokita123 Komal S.Rathi23 Maria F.Cardenas4 Kristen A.Upton1 JoyJayaseelan4 Katherine L.Cross5 JacobPfeil6 Laura E.Egolf17 Gregory P.Way8 AlvinFarrel2 Nathan M.Kendsersky19 KhushbuPatel2 Krutika S.Gaon …
Review article “Challenges and Opportunities for Childhood Cancer Drug Development” co-authored by Drs Kurmasheva and Houghton
October 3, 2019The review article “Challenges and Opportunities for Childhood Cancer Drug Development” co-authored by Raushan Kurmasheva, PhD and Peter Houghton, PhD has just been published.
Pharmacology Reviews: Challenges and Opportunities for Childhood Cancer Drug Development
October 1, 2019Peter J Houghton 1, Raushan T Kurmasheva 2 Abstract Cancer in children is rare with approximately 15,700 new cases diagnosed in the United States annually. Through the use of multimodality therapy (surgery, radiation therapy, and aggressive chemotherap …
Raushan Kurmasheva, PhD to Receive Children’s Cancer Research Fund’s “Emerging Scientist Award.”
September 13, 2019“Dr. Kurmasheva and her team have received the Emerging Scientist Award by CCRF to uncover the mechanism(s) of the interaction of the two major DNA repair pathways, and discover modulators of their interface with the goal of developing a novel therapy …
Innovation News Network: Innovative genomics and bioinformatics research at the Greehey Institute (Multiple Investigators)
June 18, 2019The past decade has witnessed a revolution in cancer research, largely driven by advances in high-throughput sequencing, functional genomics, and computational technologies. The affordability and technological maturity of high-throughput data generatio …
Clinical Cancer Research: Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models
April 25, 2019Caitlin D Lowery 1, Michele Dowless 1, Matthew Renschler 1, Wayne Blosser 1, Alle B VanWye 1, Jennifer R Stephens 1, Philip W Iversen 1, Aimee Bence Lin 1, Richard P Beckmann 1, Kateryna Krytska 2, Kristina A Cole 2, John M Maris 2, Douglas S Hawkins 3 …
Pediatric Blood & Cancer: Preclinical activity of the antibody‐drug conjugate denintuzumab mafodotin (SGN‐CD19A) against pediatric acute lymphoblastic leukemia xenografts
April 23, 2019Luke Jones, Hannah McCalmont, Kathryn Evans, Chelsea Mayoh, Raushan T. Kurmasheva, Catherine A. Billups, Peter J. Houghton, Malcolm A. Smith, Richard B. Lock Abstract Background Denintuzumab mafodotin (SGN‐CD19A) is a CD19‐targeting antibody‐drug conj …
YouTube: Experimental Biology TV, WebsEdgeMedicine
April 4, 2019https://www.youtube.com/watch?v=iWUUaz6A6Mo&t=92s “Cancers in children are rare, and the genetics and epigenetic causes are very different from those of adults. Consequently, the study of the etiology and potential therapies for these tumors requir …